CraniUS obtains scientific evidence of successful convection-enhanced delivery using patented Neuro

CraniUS becomes the first company with a smart, refillable, and fully embedded medical device that effectively bypasses the blood-brain barrier and achieves long-term, convection-enhanced medicine delivery.

BALTIMORE, Md., June 27, 2023 /PRNewswire/ -- CraniUS LLC, an R&D company focused on building groundbreaking diagnostics and treatments for patients with chronic brain diseases, announces the scientific findings of successful convection-enhanced delivery in their pre-clinical study investigating the company's patented NeuroPASS device.

The study proves the ability to achieve convection (meaningful flow and distribution of medicine beyond the catheter pathway) by delivering gadolinium through catheters with NeuroPASS, which is implanted in the skull space, invisible under the scalp. This is the first time a device has been successfully placed into the skull space allowing direct access to the brain to achieve successful convection and validates the potential for CraniUS to bring disruptive innovation to the Neuroscience and Neurosurgery markets.

Read The Full Story Here >